Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.

H Peeters,E Louis,F Baert,O Dewit,J C Coche,M Ferrante,G Lambrecht,A Colard,A Van Gossum,P Bossuyt,T Moreels,B Vander Cruyssen,A Gils,M De Vos

Acta gastro-enterologica Belgica（2018）

引用 24|浏览29

暂无评分

摘要

Switching from ADM to IFX can be efficacious in patients with loss of response, in particular in case of undetectable ADM trough levels. The majority of patients however will need IFX therapy intensification during their first year of treatment.

查看译文

关键词

Crohn's disease,adalimumab,infliximab,switching

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要